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Summary
Background Findings of large randomised trials have shown that lowering LDL cholesterol with statins reduces 
vascular morbidity and mortality rapidly, but limited evidence exists about the long-term eﬃ  cacy and safety of statin 
treatment. The aim of the extended follow-up of the Heart Protection Study (HPS) is to assess long-term eﬃ  cacy and 
safety of lowering LDL cholesterol with statins, and here we report cause-speciﬁ c mortality and major morbidity in 
the in-trial and post-trial periods. 
Methods 20 536 patients at high risk of vascular and non-vascular outcomes were allocated either 40 mg simvastatin 
daily or placebo, using minimised random isation. Mean in-trial follow-up was 5·3 years (SD 1·2), and post-trial 
follow-up of surviving patients yielded a mean total duration of 11·0 years (SD 0·6). The primary outcome  of the 
long-term follow-up of HPS was ﬁ rst post-randomisation major vascular event, and analysis was by intention to treat. 
This trial is registered with ISRCTN, number 48489393.
Findings During the in-trial period, allocation to simvastatin yielded an average reduction in LDL cholesterol of 
1·0 mmol/L and a proportional decrease in major vascular events of 23% (95% CI 19–28; p<0·0001), with signiﬁ cant 
divergence each year after the ﬁ rst. During the post-trial period (when statin use and lipid concentrations were similar 
in both groups), no further signiﬁ cant reductions were noted in either major vascular events (risk ratio [RR] 0·95 
[0·89–1·02]) or vascular mortality (0·98 [0·90–1·07]). During the combined in-trial and post-trial periods, no 
signiﬁ cant diﬀ erences were recorded in cancer incidence at all sites (0·98 [0·92–1·05]) or any particular site, or in 
mortality attributed to cancer (1·01 [0·92–1·11]) or to non-vascular causes (0·96 [0·89–1·03]).
Interpretation More prolonged LDL-lowering statin treatment produces larger absolute reductions in vascular events. 
Moreover, even after study treatment stopped in HPS, beneﬁ ts persisted for at least 5 years without any evidence of 
emerging hazards. These ﬁ ndings provide further support for the prompt initiation and long-term continuation of 
statin treatment.
Funding UK Medical Research Council, British Heart Foundation, Merck & Co, Roche Vitamins.
Introduction
The Medical Research Council and British Heart 
Foundation (MRC/BHF) Heart Protection Study (HPS), 
among 20 000 patients at high risk of vascular and non-
vascular outcomes, was established to assess the long-
term eﬃ  cacy and safety of lowering LDL cholesterol 
concentrations substantially with statin treatment.1 
Collectively, ﬁ ndings of HPS and other major trials of 
statins provide compelling evidence that lowering LDL 
cholesterol by about 1 mmol/L reduces vascular mortality 
and morbidity by about a quarter in a wide range of 
patients (including elderly people and those with low 
cholesterol concentrations), without increasing the risk 
of non-vascular mortality or morbidity (apart from a 
small myopathy excess) during about 5 years of 
treatment.2–4 As a result, many people are now prescribed 
long-term statin treatment to reduce their vascular risk.
During prolonged follow-up in observational epi-
demiological studies, lower blood cholesterol concen-
trations have been associated with higher rates of 
particular types of cancer, and with other non-vascular 
morbidity and mortality.5,6 It has been suggested, 
therefore, that lowering LDL cholesterol (particularly to 
low levels) might produce increases in the rates of cancers 
and other types of adverse events that take longer than 
5 years to emerge.7–9 Only limited evidence about long-
term safety has been reported from statin trials.10–14 We 
aimed to assess the eﬀ ects of lowering LDL cholesterol 
on cause-speciﬁ c mortality and major morbidity, not only 
during the study treatment period in HPS but also in the 
longer term, post-trial.
Methods
Patients and randomisation
Details of HPS have been reported previously.1–3 Brieﬂ y, 
between July, 1994, and May, 1997, 20 536 men and 
women aged about 40–80 years, who were at increased 
risk of vascular events, were randomly allocated to receive 
40 mg simvastatin daily or matching placebo. At the 
ﬁ nal follow-up (May–October, 2001), participants were 
encouraged to continue their allocated study treatment 
(unless it was contraindicated) until the study results 
For more on HPS see 
http://www.hpsinfo.org
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were sent to them and their family doctors on Nov 11, 2001. 
Participants were advised to discuss with their doctors, in 
light of those results, whether non-trial statin treatment 
should be prescribed (and study treatment stopped). To 
allow unbiased assessment of subsequent long-term 
eﬀ ects, participants and their doctors were not made 
aware of their previously allocated study treatment unless 
there was a particular request to do so, and only 15% of 
participants were unblinded (18% simvastatin-allocated 
vs 13% placebo-allocated).
Procedures and follow-up
During the in-trial treatment period, routine follow-up in 
study clinics was at 4, 8, and 12 months and then every 
6 months. Information was sought about any suspected 
heart attacks, strokes, vascular procedures, cancers, or 
other serious adverse events. Participants unable or 
unwilling to attend were contacted by telephone, or 
follow-up was sought from their family doctors. Post-trial 
follow-up of serious adverse events was conducted by 
mailing questionnaires to all surviving participants 
in late November, 2001, and then annually until 
November, 2006, with a reminder mailed about 2 months 
later. Follow-up of participants who did not complete 
questionnaires was sought from their family doctors. 
During both the in-trial and post-trial periods, information 
about the sites of registered cancers and certiﬁ ed causes 
of deaths was requested from UK national registries for 
all randomised patients.
Further details were sought from the participants’ 
family doctors (plus, if necessary, hospital records) about 
all reports that might relate to major vascular events or 
deaths. In view of the high conﬁ rmation rate (>95%) in 
central adjudication of cancers reported during the 
in-trial period, further information was not routinely 
sought about non-fatal cancers reported during the post-
trial period. Events were coded according to prespeciﬁ ed 
criteria1 by clinical staﬀ  in the coordinating centre, who 
were unaware of the study treatment allocation.
During the in-trial period, compliance with study 
treatment was assessed at each follow-up by questioning 
the participant and reviewing their remaining calendar-
packed tablets. The eﬀ ects of treatment allocation on 
cholesterol concentrations were assessed by assaying 
blood obtained at study clinics from a sample of about 
5% of participants scheduled for follow-up at about the 
same time each year, and from all participants attending 
follow-up between August, 2000, and February, 2001.2 
During the post-trial period, participants were asked 
each year about their current statin use, and post-trial 
lipid proﬁ le assays were sought from 1500 randomly 
selected surviving participants between May, 2004, and 
August, 2004 (ie, about 3 years after the scheduled 
treatment period). About 1100 blood samples were 
obtained by participants’ family doctors and were mailed 
to a central laboratory for assay using previously 
validated methods.15
Endpoints and statistical analysis
The main comparisons entail log-rank analyses of the 
ﬁ rst post-randomisation occurrence of particular events 
during the in-trial period (deﬁ ned as events occurring 
Simvastatin-allocated Placebo-allocated
Year 0 7370/8863 (83%) 7066/8656 (82%)
Year 1 7152/8542 (84%) 6845/8317 (82%)
Year 2 6525/8181 (80%) 6284/7950 (79%)
Year 3 6023/7810 (77%) 5821/7594 (77%)
Year 4 6651/7431 (90%) 6462/7204 (90%)
Year 5 5375/7063 (76%) 5165/6860 (75%)
Data are completed/alive at start of year. Completed=questionnaire or family 
doctor response (higher response rates during year 4 indicate intensive eﬀ orts to 
contact family doctors).
Table 1: Post-trial follow-up of outcomes (other than cancer and death), 
by year of follow-up 
Simvastatin-allocated Placebo-allocated
In-trial
Year 1 8994/10 107 (89%) 389/10 088 (4%)
Year 2 8457/9909 (85%) 889/9826 (9%)
Year 3 8122/9664 (84%) 1608/9563 (17%)
Year 4 7764/9388 (83%) 2262/9241 (24%)
Year 5 6058/7370 (82%) 2345/7225 (32%)
Average 85% 17%
Post-trial
Year 1 4163/7152 (58%) 4113/6845 (60%)
Year 2 4555/6525 (70%) 4381/6284 (70%)
Year 3 4665/6023 (77%) 4489/5821 (77%)
Year 4 5363/6651 (81%) 5136/6462 (79%)
Year 5 4527/5375 (84%) 4294/5165 (83%)
Average 74% 74%
Data show statin use/alive (in-trial) and statin use/completed forms (post-trial).
Table 2: In-trial and post-trial statin use (study and non-study), by year 
of follow-up
Simvastatin-allocated Placebo-allocated Absolute diﬀ erence
Total cholesterol (mmol/L)
Baseline 5·9 (0·01) 5·9 (0·01) 0·0 (0·01)
In-trial 4·2 (0·01) 5·4 (0·01) 1·2 (0·02)
Post-trial 4·3 (0·04) 4·4 (0·04) 0·0 (0·06)
LDL cholesterol (mmol/L)
Baseline 3·4 (0·01) 3·4 (0·01) 0·0 (0·01)
In-trial 2·3 (0·01) 3·3 (0·01) 1·0 (0·02)
Post-trial 2·6 (0·03) 2·6 (0·03) 0·0 (0·05)
In-trial lipid proﬁ les are study averages based on assays in a selected sample of 5% of participants each year and in all 
participants during the ﬁ nal year of the scheduled treatment period. Post-trial lipid proﬁ les were measured in a random 
sample of 1175 participants after 3·2 years of post-trial follow-up.
Table 3: In-trial and post-trial mean (SE) lipid levels
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up to Nov 11, 2001) and during the post-trial period 
(deﬁ ned as events occurring from Nov 11, 2001, until 
March 31, 2007) among all those originally allocated 
40 mg simvastatin daily versus all those allocated 
matching placebo tablets (ie, intention-to-treat analyses). 
The results of these in-trial analyses diﬀ er slightly from 
previously published ﬁ ndings2,3 because of the inclusion 
of events taking place between the participants’ ﬁ nal 
follow-up visit and Nov 11, 2001 (mean extra follow-up of 
3·5 months [SD 1·4]). The primary outcome for analyses 
of prolonged follow-up was prespeciﬁ ed to be the ﬁ rst 
post-randomisation major vascular event (deﬁ ned as 
non-fatal myocardial infarction or coronary death, fatal 
or non-fatal stroke, coronary or non-coronary revas cu-
larisation). Secondary outcomes were: major vascular 
events during each year of follow-up and in various 
subcategories of patients; major coronary events (ie, non-
fatal myocardial infarction or coronary death), strokes, 
and revascular isations separately; deaths from vascular 
and non-vascular causes separately; and cancers at all 
sites (excluding non-melanoma skin cancer). Analyses 
are presented of other outcomes, some of which (eg, site-
speciﬁ c cancer, cerebral haemorrhage) were prespeciﬁ ed 
for the in-trial period whereas some were not (eg, cancer 
incidence each year). Allowances for multiple compari-
sons and for the post-hoc nature of such analyses were 
made in their interpretation.
Role of the funding source
The trial was designed, conducted, analysed, and 
interpreted by the investigators, independently of all 
funding sources. The writing committee had full access 
to the study data and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Mean follow-up during the in-trial period for all 
randomised participants was 5·3 years (SD 1·2), and the 
mean total follow-up for participants who survived to the 
end of the post-trial period was 11·0 years (SD 0·6). Of 
20 536 participants, 17 519 were still alive at the start of the 
post-trial follow-up period: 8863 allocated simvastatin 
versus 8656 placebo (ratio 1·02; because simvastatin 
reduced mortality).2 Overall, 96 784 person-years of 
follow-up were available for those originally allocated 
simvastatin and 95 084 for those allocated placebo 
(ratio 1·02). Response rates to mailed questionnaires and 
from family doctors during the post-trial period were high 
and did not diﬀ er by previous statin allocation (table 1). 
All but 74 participants (42 simvastatin and 32 placebo) 
could be followed up for cancer reports and death 
certiﬁ cation through national registries. 
During the in-trial period, the average diﬀ erence in 
statin use between simvastatin-allocated versus placebo-
allocated patients was 67% (85% vs 17%), resulting in an 
average LDL cholesterol diﬀ erence of 1·0 mmol/L 
(SE 0·02).2 During the post-trial period, self-reported 
statin use was similar in both groups, rising from about 
59% at the end of the ﬁ rst year to 84% by the end of the 
ﬁ fth year (table 2). This similarity in statin use between 
groups was supported by similar LDL cholesterol 
concentrations (2·6 [SE 0·03] vs 2·6 [0·03] mmol/L; 
p=0·7: table 3) after 3·2 years of post-trial follow-up.
During the in-trial period, 2153 (21·0%) ﬁ rst major 
vascular events arose in 10 269 participants allocated 
simvastatin versus 2712 (26·4%) in 10 267 allocated 
placebo, corresponding to a signiﬁ cant 23% (SE 3) 
proportional reduction (p<0·0001: ﬁ gure 1). No signiﬁ cant 
diﬀ erence was noted during the ﬁ rst year, but signiﬁ cant 
1·0 1·2 1·40·80·60·4
In-trial events
Major coronary event
Stroke
Revascularisation
Major vascular event
Post-trial events
Major coronary event
Stroke
Revascularisation
Major vascular event
959/10 269 (9·3%)
480/10 269 (4·7%)
981/10 269 (9·6%)
2153/10 269 (21·0%)
1032/8553 (12·1%)
426/8544 (5·0%)
671/8015 (8·4%)
1636/7543 (21·7%)
 1287/10 267 (12·5%)
 619/10 267 (6·0%)
 1258/10 267 (12·3%)
 2712/10 267 (26·4%)
 1021/8172 (12·5%)
 419/8246 (5·1%)
 672/7572 (8·9%)
 1566/6967 (22·5%)
0·73 (0·67–0·79)
0·76 (0·68–0·86)
0·76 (0·70–0·83)
0·77 (0·72–0·81)
0·96 (0·88–1·04)
0·98 (0·86–1·12)
0·93 (0·84–1·04)
0·95 (0·89–1·02)
p<0·0001
p=0·17
Simvastatin allocation Risk ratio (95% CI) p value
Simvastatin Placebo
Favours simvastatin Favours placebo
Figure 1: First major vascular event during in-trial and post-trial follow-up
Analyses are of numbers of participants having a ﬁ rst post-randomisation event of each type during follow-up, so there is some non-additivity between diﬀ erent 
types of event. Denominators during the post-trial period are the numbers of randomised patients who had not had the particular outcome or died during the in-trial 
period. Risk ratios (RRs) are plotted (black squares with area proportional to amount of statistical information in each subdivision) comparing outcome among the 
participants allocated 40 mg simvastatin daily to that among those allocated placebo, along with their 95% CIs (horizontal lines; ending with arrow head when CI 
extends beyond scale). For particular subtotals and totals, the result and its 95% CI are represented by a diamond, with the relative risk reduction (and 95% CI) and 
statistical signiﬁ cance given alongside. A broken vertical line indicates the overall RR.
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reductions of about a quarter were seen during each 
subsequent in-trial year (ﬁ gure 2). Among event-free 
survivors at the start of the post-trial period, 1636 (21·7%) 
ﬁ rst events arose in patients previously allocated 
simvastatin versus 1566 (22·5%) in those previously 
allocated placebo (risk ratio [RR] 0·95 [95% CI 0·89–1·02]; 
p=0·17). A further decrease of 14% ([0–26]; p=0·05) was 
recorded in the ﬁ rst post-trial year in patients originally 
allocated simvastatin, but little diﬀ erence was seen 
between treatment groups thereafter. As a result, the 
cumulative proportions of participants who had major 
vascular events diverged throughout the in-trial period, 
and this separation then persisted roughly unchanged 
throughout the post-trial period (ﬁ gure 3). The eﬀ ects of 
statin allocation on major vascular events during the 
in-trial and post-trial periods were unaﬀ ected by age or 
pretreatment lipid proﬁ les (webappendix p 3).
Similar patterns were seen for each component of major 
vascular events (ﬁ gure 1). For major coronary events, a 
27% (SE 4) reduction was noted during the in-trial period 
(p<0·0001). During the post-trial period, the incidence 
rates were similar in both treatment groups (RR 0·96 
[95% CI 0·88–1·04]; p=0·31), although a further reduction 
was recorded in ﬁ rst non-fatal myocardial infarction 
(413 [4·8%] vs 465 [5·7%]; p=0·01). For strokes, a 
24% (SE 5) reduction was seen during the in-trial period 
(p<0·0001), reﬂ ecting a 29% (SE 6) reduction in deﬁ nite 
ischaemic stroke and no diﬀ erence in haemorrhagic 
stroke (51 [0·5%] vs 56 [0·5%]; p=0·59). During the post-
trial period, the incidence rates were similar in both 
treatment groups (0·98 [0·86–1·12]; p=0·77), with no 
adverse eﬀ ect on haemorrhagic stroke (38 [0·4%] vs 
51 [0·6%]; p=0·13). For revascularisation procedures, a 
signiﬁ cant 24% (SE 4) reduction was seen during the 
in-trial period (p<0·0001). During the post-trial period, the 
incidence rates were similar in both treatment groups 
(0·93 [0·84–1·04]; p=0·20).
Vascular mortality during the in-trial period accounted 
for 826 (8·0%) deaths in participants allocated simvastatin 
versus 998 (9·7%) in those allocated placebo, corres-
ponding to an 18% (SE 4) proportional reduction (p<0·0001, 
ﬁ gure 4; webappendix, p 4). During the post-trial period, 
vascular mortality rates were similar in both treatment 
groups (1019 [11·5%] vs 1007 [11·6%]; RR 0·98 [95% CI 
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Figure 3: First major vascular event during total follow-up period
Life-table plot of the eﬀ ects of simvastatin allocation on percentage of major vascular events during the in-trial 
and post-trial periods.
See Online for webappendix
1·0 1·2 1·40·80·60·4
In-trial
Year 1
Year 2
Year 3
Year 4
Year 5+
All in-trial
Post-trial
Year 1
Year 2
Year 3
Year 4
Year 5+
All post-trial
 482/10 269 (4·7%)
 378/9744 (3·9%)
 361/9286 (3·9%)
 333/8814 (3·8%)
 599/8352 (7·2%)
 2153/10 269 (21·0%)
 
 320/7543 (4·2%)
 343/7099 (4·8%)
 332/6610 (5·0%)
 291/6125 (4·8%)
 350/5677 (6·2%)
 1636/7543 (21·7%)
 529/10 267 (5·2%) 
 538/9681 (5·6%)
 507/9053 (5·6%)
 442/8463 (5·2%)
 696/7893 (8·8%)
 2712/10 267 (26·4%)
 341/6967 (4·9%)
 333/6487 (5·1%)
 313/6024 (5·2%)
 274/5573 (4·9%)
 305/5156 (5·9%)
 1566/6967 (22·5%)
Simvastatin allocation Risk ratio (95% CI) p value
Simvastatin Placebo
Favours simvastatin Favours placebo
p<0·0001
p=0·17
0·91 (0·80–1·03)
0·69 (0·61–0·79)
0·69 (0·61–0·79)
0·72 (0·62–0·83)
0·80 (0·72–0·89)
0·77 (0·72–0·81)
0·86 (0·74–1·00)
0·94 (0·81–1·09)
0·96 (0·83–1·13)
0·96 (0·82–1·14)
1·05 (0·90–1·22)
0·95 (0·89–1·02)
Figure 2: First major vascular event by year during in-trial and post-trial follow-up
Conventions as in ﬁ gure 1. Denominators are the numbers of patients at risk of a ﬁ rst post-randomisation major vascular event at the start of each year.
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0·90–1·07]; p=0·71), so in-trial survival gains persisted. 
The eﬀ ects of statin allocation on vascular mortality in both 
the in-trial and post-trial periods were unaﬀ ected by age or 
pretreatment lipid proﬁ les (webappendix, p 5).
Non-vascular mortality during the in-trial period 
accounted for 580 (5·6%) deaths in participants allocated 
simvastatin versus 613 (6·0%) in those allocated placebo 
(p=0·25; ﬁ gure 4). A marginally signiﬁ cant reduction in 
deaths attributed to respiratory disease was noted in 
simvastatin-allocated participants (95 [0·9%] vs 124 [1·2%]; 
p=0·04), but deaths from cancer, or other prespeciﬁ ed 
categories of non-vascular death, did not diﬀ er 
signiﬁ cantly (webappendix, p 4). During the post-trial 
period, non-vascular mortality rates were similar in both 
treatment groups (943 [10·6%] vs 942 [10·9%]; RR 0·97 
[95% CI 0·89–1·06]; p=0·55), with no diﬀ erences 
reported in deaths from cancer, respiratory disease, or 
non-medical causes. The apparent reduction in deaths 
attributed to other medical causes in participants 
originally allocated simvastatin (200 [2·3%] vs 239 [2·8%]) 
was only marginally signiﬁ cant (p=0·03) and involved no 
material diﬀ erences in deaths due to renal or hepatic 
disease and only a non-signiﬁ cant diﬀ erence in a 
miscellaneous group of other non-vascular causes. 
Despite previous concerns about the safety of lipid-
lowering treatment in elderly people and those with 
below-average cholesterol concentrations,7,8 there was no 
evidence of any adverse eﬀ ect on non-vascular mortality 
in statin-allocated par ticipants aged 70 or older at 
baseline, or those with pretreatment total cholesterol 
concentrations less than 5·0 mmol/L (webappendix, p 6). 
When the 11 years of in-trial and post-trial follow-up are 
considered together, allocation to about 5 years of statin 
treatment was not associated with any increase in non-
vascular mortality, either overall (1523 [14·8%] vs 
1555 [15·1%]; RR 0·96 [95% CI 0·89–1·03]; p=0·24) or 
for any prespeciﬁ ed category of death.
The 14% (SE 3) proportional reduction in all-cause 
mortality (p=0·0001) seen during the in-trial period 
reﬂ ects the combination of an 18% (SE 4) proportional 
reduction in vascular mortality and little eﬀ ect on non-
vascular mortality (webappendix p 4). During the post-
trial period, there was no further reduction in vascular 
mortality and no emergence of any adverse eﬀ ect on 
In-trial
Vascular death
Non-vascular death
Post-trial
Vascular death
Non-vascular death
Simvastatin allocation Risk ratio (95% CI)
Simvastatin Placebo
 826/10 269 (8·0%)
 580/10 269 (5·6%)
 1019/8863 (11·5%)
 943/8863 (10·6%)
 998/10 267 (9·7%)
 613/10 267 (6·0%)
 1007/8656 (11·6%)
 942/8656 (10·9%)
0·82 (0·75–0·90)
0·94 (0·83–1·05)
0·98 (0·90–1·07)
0·97 (0·89–1·06)
1·0 1·2 1·40·80·60·4
Favours simvastatin Favours placebo
Figure 4: Vascular and non-vascular mortality during in-trial and post-trial follow-up
Conventions as in ﬁ gure 1.
Year of follow-up
1
2
3
4
5
6
7
8
9
10+
Whole study period
Simvastatin allocation Risk ratio (95% CI)
Simvastatin Placebo
 119/10 269 (1·2%)
 157/10 019 (1·6%)
 157/9728 (1·6%)
 169/9400 (1·8%)
 181/9047 (2·0%)
 165/8650 (1·9%)
 163/8258 (2·0%)
 177/7898 (2·2%)
 161/7466 (2·2%)
 300/7049 (4·3%)
 1749/10 269 (17·0%)
 119/10 267 (1·2%)
 147/10 001 (1·5%)
 168/9643 (1·7%)
 183/9276 (2·0%)
 171/8879 (1·9%)
 174/8474 (2·1%)
 152/8056 (1·9%)
 166/7656 (2·2%)
 167/7246 (2·3%)
 297/6820 (4·4%)
 1744/10 267 (17·0%)
1·00 (0·77–1·29)
1·06 (0·85–1·33)
0·92 (0·74–1·15)
0·91 (0·74–1·12)
1·04 (0·84–1·28)
0·93 (0·75–1·15) 
1·04 (0·83–1·30)
1·03 (0·84–1·28)
0·93 (0·75–1·16)
0·98 (0·84–1·15)
0·98 (0·92–1·05)
1·0 1·2 1·40·80·60·4
Favours simvastatin Favours placebo
Figure 5: First incident cancer by year during total follow-up period
Conventions as in ﬁ gure 1.
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non-vascular mortality; the proportions of participants 
who died were similar in both treatment groups 
(1962 [22·1%] vs 1949 [22·5%]; RR 0·98 [95% CI 
0·92–1·04]; p=0·49). As a result, the absolute reduction 
in all-cause mortality that emerged with simvastatin 
allocation during the in-trial period persisted roughly 
unchanged after 11 years of follow-up.
The incidence of a ﬁ rst diagnosis of any type of cancer 
(excluding, as prespeciﬁ ed, non-melanoma skin cancer) 
was similar throughout the in-trial and post-trial periods 
combined (1749 [17·0%] allocated simvastatin vs 
1744 [17·0%] allocated placebo; RR 0·98 [0·92–1·05]; 
p=0·60; ﬁ gure 5). Indeed, even during the later years of 
this prolonged follow-up, no suggestion was noted of any 
emerging diﬀ erence in the overall incidence of cancer. If 
cholesterol lowering with statin treatment had eﬀ ects on 
cancer then these might be expected to be restricted to 
particular types.9,16 The large numbers of incident cancers 
recorded during the combined in-trial and post-trial 
periods allow reliable assessment of the eﬀ ects of a 
substantial 5-year reduction in cholesterol on 11-year risks 
of the commoner types of cancer. The incidence of 
genitourinary, gastrointestinal, respiratory, haemato-
logical, or any other malignant disease did not diﬀ er 
signiﬁ cantly (ﬁ gure 6), even in patients aged 70 years or 
older at baseline or with below-average pretreatment 
cholesterol concentrations (webappendix, p 7).
Discussion
Prolonged post-trial follow-up of participants in HPS 
shows that the substantial reduction in vascular 
mor tality and morbidity produced during an average 5-year 
reduction in LDL cholesterol of 1 mmol/L with simvastatin 
persisted largely unchanged during the subsequent 6 years. 
Reassuringly, there was no evidence that any adverse eﬀ ect 
on particular causes of non-vascular mortality or major 
morbidity (including site-speciﬁ c cancers) was emerging 
during this prolonged follow-up period (panel).
Study treatment was not routinely unblinded at the end 
of the in-trial period of HPS, and no diﬀ erences between 
treatment groups were recorded in statin use or LDL 
cholesterol concentrations during post-trial follow-up. In 
each year of post-trial follow-up, about a ﬁ fth of the 
surviving participants did not return their postal 
questionnaire, but information about non-fatal clinical 
events was obtained from family doctors for about half of 
these non-responders, and the completeness of follow-up 
was similar in the two treatment groups. Furthermore, 
information on site-speciﬁ c cancers and cause-speciﬁ c 
mortality was obtained from national registries for almost 
all randomised patients throughout both the in-trial and 
the post-trial periods. As a result, although the power to 
detect any eﬀ ects might have been reduced slightly by 
some events having been missed, this occurrence should 
not have introduced any bias. Hence, the large numbers 
of major vascular events that were recorded during the 
post-trial period of follow-up in HPS provide robust 
evidence about the persistence of the cardio vascular 
beneﬁ ts produced by previous statin treatment. Similarly, 
the large numbers of other types of outcome recorded 
during prolonged follow-up provide compelling evidence 
that 5 years of statin therapy is not associated with 
excesses of any particular type of non-vascular death, site-
speciﬁ c cancer, or other major non-vascular morbidity. 
Moreover, although 11 years might still not be long enough 
for deleterious eﬀ ects on cancer to emerge fully, no 
adverse trend was noted, even during the later years of 
post-trial follow-up.
The ﬁ ndings of HPS for persistence of vascular beneﬁ ts 
are generally consistent with the results for follow-up 
beyond the scheduled treatment period from four other 
large (>1000 participants) randomised trials of statin 
treatment (webappendix p 1; one other such trial has only 
reported the results for the in-trial and post-trial period 
combined).14 In 4S,10 in which over 4000 people with 
coronary disease were studied, vascular mortality during 
Cancer site
Gastrointestinal
Respiratory
Connective tissue
Genitourinary
CNS
Haematological
Other
Not speciﬁed
Any cancer
Simvastatin allocation Risk ratio (95% CI)
Simvastatin (n=10 269) Placebo (n=10 267)
 468 (4·6%)
 369 (3·6%)
 141 (1·4%)
 622 (6·1%)
 29 (0·3%)
 166 (1·6%)
 15 (0·1%)
 90 (0·9%)
 1749 (17·0%)
 483 (4·7%)
 356 (3·5%)
 154 (1·5%)
 609 (5·9%)
 21 (0·2%)
 161 (1·6%)
 14 (0·1%)
 99 (1·0%)
 1744 (17·0%)
0·95 (0·84–1·08)
1·02 (0·88–1·18)
0·90 (0·71–1·13)
1·00 (0·89–1·12)
1·35 (0·77–2·35)
1·01 (0·81–1·25)
1·05 (0·51–2·17)
0·89 (0·67–1·19)
0·98 (0·92–1·05)
1·0 1·2 1·40·80·60·4
Favours simvastatin Favours placebo
Figure 6: Incidence of site-speciﬁ c cancer during total follow-up period
Conventions as in ﬁ gure 1. Not including non-melanoma skin cancer, which was prospectively to be considered separately (561 [5·5%] vs 512 [5·0%]; risk ratio 1·08 
[0·96–1·21]; p=0·22). 
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5 years of post-trial follow-up was non-signiﬁ cantly higher 
among those originally allocated simvastatin, but non-fatal 
vascular events were not reported. Perhaps due to routine 
unblinding at the end of the in-trial period, use of 
cholesterol-lowering drugs (usually simvastatin) after 
3 years of post-trial follow-up was slightly higher among 
participants originally allocated simvastatin (86% vs 82%). 
In LIPID,11 in which over 9000 people with coronary disease 
were included, vascular mortality during 2 years of post-
trial follow-up was signiﬁ cantly (p=0·02) lower among 
those originally allocated pravastatin. After routine 
unblinding at the end of the in-trial period, both groups 
were encouraged to take pravastatin 40 mg daily and 
similar proportions commenced it (88% vs 86%), and blood 
lipid levels were similar during each of the post-trial years. 
In WOSCOPS,12 in which over 6000 men without known 
coronary disease were enrolled, signiﬁ cantly fewer non-
fatal myocardial infarctions or coronary deaths (p=0·02) 
and non-signiﬁ cantly fewer strokes (p=0·22) were seen 
during 10 years of post-trial follow-up. Again, perhaps due 
to routine unblinding, a slightly higher proportion of those 
originally allocated pravastatin were taking statins during 
the ﬁ rst 5 years of post-trial follow-up (29% vs 24% at 1 year 
and 39% vs 35% at 5 years). In ASCOT-LLA,13 which 
involved 10 000 people with hypertension, the incidence of 
non-fatal myocardial infarction or coronary death during 
2 years of post-trial follow-up was signiﬁ cantly (p=0·005) 
lower among those originally allocated atorvastatin. At the 
end of the lipid-lowering treatment period, atorvastatin 
was oﬀ ered to all participants (who were not routinely 
unblinded) and a slightly higher proportion of those 
originally allocated atorvastatin were taking statin treatment 
at the end of the post-trial period (67% vs 63%), although 
lipid proﬁ les were broadly similar.
Concerns have been raised that lower blood cholesterol 
concentrations could be associated with an increased 
incidence of cancer or some other non-vascular 
outcomes.5,6,9,16 The Cholesterol Treatment Trialists’ meta-
analysis of about 130 000 patients in 21 trials of statin 
versus control (including HPS), which included about 
7000 incident cancers and 3000 non-vascular deaths 
during an average 5-year LDL cholesterol reduction of 
1 mmol/L, did not ﬁ nd any excess of particular types of 
cancer or non-vascular death.4 But, if adverse eﬀ ects were 
caused by lowering cholesterol then they might only 
emerge after longer term follow-up. Previously, the 
numbers and types of non-vascular outcomes reported 
from prolonged post-trial follow-up in statin trials have 
been limited (webappendix p 2). In ASCOT-LLA,13 only 
mortality during 2 years of post-trial follow-up was 
reported, with previous allocation to atorvastatin not 
associated with an excess in non-vascular mortality. 
Furthermore, the LIPID study group has only reported 
2 years of post-trial follow-up,11 with no signiﬁ cant 
diﬀ erences in deaths from all types of non-vascular cause 
combined or in incidence of cancers at all sites combined. 
4S has reported 5 years of post-trial follow-up,10 with no 
apparent diﬀ erences in all types of non-vascular mortality 
or cancer incidence at all sites. 10 years of post-trial 
follow-up has been reported in WOSCOPS,12 with no 
apparent diﬀ erences in total non-vascular mortality or 
cancer incidence. In WOSCOPS, more of the men 
originally allocated pravastatin did have prostate cancer 
diagnosed during the combined follow-up period 
(89 [2·7%] vs 59 [1·8%]), but there were few such cancers 
and the diﬀ erence was not statistically convincing 
(p=0·03). The much larger numbers of men in HPS who 
were found to have developed prostate cancer (367 [4·7%] 
simvastatin vs 348 [4·5%] placebo) during 11 years of 
follow-up show that substantial reductions in cholesterol 
with statin treatment do not materially increase its 
incidence (1·03 [0·89–1·20]; p=0·67).
In HPS, among participants allocated simvastatin, 
fewer major vascular events were noted in the ﬁ rst year 
after randomisation and signiﬁ cant reductions of about a 
quarter were seen in each separate year of the in-trial 
period. These ﬁ ndings suggest that the absolute beneﬁ ts 
of prolonged statin treatment are likely to be much 
greater than is indicated by analyses restricted merely to 
in-trial periods of statin trials. Moreover, even after in-
study statin treatment stopped in HPS, the beneﬁ ts 
persisted for several years. As well as providing reliable 
evidence about the long-term beneﬁ ts of statin therapy, 
the large numbers of other major health outcomes 
recorded during prolonged follow-up in HPS provide 
considerable reassurance—both to prescribers and to 
Panel: Research in context 
Systematic review
Electronic searches of Medline, PubMed, and Scopus, 
supplemented by hand searches of reference lists of 
meta-analyses and other review articles, identiﬁ ed reports 
from ﬁ ve large randomised trials of statin therapy with 
post-trial follow-up of clinical outcomes. These previous 
reports included limited numbers of major vascular events, 
incident cancers, and non-vascular deaths during prolonged 
post-trial follow-up, making reliable assessment of 
persistence of beneﬁ t or emergence of any hazard diﬃ  cult.
Interpretation
Prolonged follow-up in the Heart Protection Study now 
shows that reduction of about a quarter in vascular mortality 
and morbidity—produced by an average 1 mmol/L reduction 
in LDL cholesterol with 5 years of statin therapy—persisted 
largely unchanged during the subsequent 6 years, despite 
similar LDL cholesterol concentrations and statin use in both 
treatment groups. Reassuringly, no adverse eﬀ ects on 
particular causes of non-vascular mortality or major 
morbidity (including site-speciﬁ c cancers) were seen to 
emerge during prolonged follow-up. These ﬁ ndings support 
prompt initiation and long-term continuation of statin 
treatment in people at increased risk of vascular events. 
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patients—about the long-term safety of lowering LDL 
cholesterol sub stantially for about 5 years. These ﬁ ndings 
provide further support for the prompt initiation and 
long-term continuation of statin treatment in people at 
increased risk of vascular events.
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